ATE170076T1 - Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen - Google Patents

Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen

Info

Publication number
ATE170076T1
ATE170076T1 AT94102791T AT94102791T ATE170076T1 AT E170076 T1 ATE170076 T1 AT E170076T1 AT 94102791 T AT94102791 T AT 94102791T AT 94102791 T AT94102791 T AT 94102791T AT E170076 T1 ATE170076 T1 AT E170076T1
Authority
AT
Austria
Prior art keywords
angiotensin
antagonists
treatment
viral diseases
diseases
Prior art date
Application number
AT94102791T
Other languages
English (en)
Inventor
Akira Matsumori
Original Assignee
Takeda Chemical Industries Ltd
Akira Matsumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Akira Matsumori filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE170076T1 publication Critical patent/ATE170076T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT94102791T 1993-02-26 1994-02-24 Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen ATE170076T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3823493 1993-02-26

Publications (1)

Publication Number Publication Date
ATE170076T1 true ATE170076T1 (de) 1998-09-15

Family

ID=12519615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94102791T ATE170076T1 (de) 1993-02-26 1994-02-24 Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen

Country Status (8)

Country Link
US (2) US5605919A (de)
EP (1) EP0612524B1 (de)
JP (1) JP2787539B2 (de)
AT (1) ATE170076T1 (de)
CA (1) CA2116388C (de)
DE (1) DE69412662T2 (de)
DK (1) DK0612524T3 (de)
ES (1) ES2121103T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6037456A (en) * 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
KR20030016229A (ko) * 2000-02-18 2003-02-26 다케다 야쿠힌 고교 가부시키가이샤 ＴＮＦ-α 억제제
US20060135422A1 (en) * 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
CA2597444A1 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
HRP20100542T1 (hr) 2005-09-16 2010-11-30 Arrow Therapeutics Limited Derivati bifenila i njihova uporaba za liječenje hepatitisa c
CA2681143C (en) * 2007-03-28 2017-01-03 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
WO2009148961A2 (en) * 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
US20100317706A1 (en) * 2009-04-30 2010-12-16 Bumham Institute For Medical Research HNF4alpha MODULATORS AND METHODS OF USE
MX2019015167A (es) * 2017-06-13 2020-08-03 Commw Scient Ind Res Org Farmacos antivirales.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
CA1279648C (en) * 1986-07-11 1991-01-29 Haruo Kuriyama 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
EP0665215A1 (de) * 1990-06-01 1995-08-02 The Du Pont Merck Pharmaceutical Company 1,4-Diamino-2,3-dihydroxybutanen
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤

Also Published As

Publication number Publication date
JP2787539B2 (ja) 1998-08-20
DE69412662T2 (de) 1999-01-07
EP0612524B1 (de) 1998-08-26
JPH06305965A (ja) 1994-11-01
CA2116388A1 (en) 1994-08-27
US5750551A (en) 1998-05-12
ES2121103T3 (es) 1998-11-16
DE69412662D1 (de) 1998-10-01
US5605919A (en) 1997-02-25
EP0612524A1 (de) 1994-08-31
CA2116388C (en) 2007-03-13
DK0612524T3 (da) 1999-05-25

Similar Documents

Publication Publication Date Title
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE61523T1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
ATE170076T1 (de) Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE535255T1 (de) Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
GB0130677D0 (en) Medicaments and novel compounds
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
BG103512A (en) Substituted pyramidine compounds and their application
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification